Across TCGA pan-cancer cohorts, MITF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MITF data layer compared with 18 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MITF mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MITF expression acts as an unfavorable survival marker.
HNSC, PDAC, and LUAD are the cancer types where MITF mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.